Literature DB >> 11940202

Overexpression of osteopontin in hepatocellular carcinoma.

Masahiro Gotoh1, Michiie Sakamoto, Kengo Kanetaka, Makoto Chuuma, Setsuo Hirohashi.   

Abstract

Human hepatocellular carcinoma (HCC) is one of the most common and aggressive malignancies. In order to identify genes involved in HCC progression, we conducted a differential display analysis and found osteopontin (OPN) to be overexpressed in HCC. OPN is known to be a secreted adhesive glycoprotein, associated with tumorigenesis and metastasis in several cancers. Quantitative polymerase chain reaction analysis of 30 HCC cases revealed the average ratio of OPN to glyceraldehyde-3-phosphate dehydrogenase in tumors to be significantly higher than that in the surrounding non-cancerous liver (4.7 +/- 1.6 vs 0.18 +/- 0.04, P = 0.0072). Immunohistochemistry confirmed the OPN protein was expressed mainly on cancer cells, and was positive in 12 of 30 HCC, most of which showed transcript overexpression. Both OPN transcript and OPN protein were significantly overexpressed in HCC with capsular infiltration, compared with HCC without capsular infiltration. Moreover, OPN-positive cancer cells were often dispersed in the periphery of cancer nodules and were adjacent to stromal cells. Although OPN overexpression was not related to vascular invasion or intrahepatic metastasis, OPN was suggested to play a role in HCC, especially in cancer-stromal interactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11940202     DOI: 10.1046/j.1440-1827.2002.01316.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  51 in total

1.  Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells.

Authors:  Fan Lin; Yuyuan Li; Jie Cao; Shaofeng Fan; Jifeng Wen; Guanghui Zhu; Hong Du; Yanxiao Liang
Journal:  Mol Biol Rep       Date:  2010-12-29       Impact factor: 2.316

2.  Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas.

Authors:  Jian-Hua Luo; Baoguo Ren; Sergei Keryanov; George C Tseng; Uma N M Rao; Satdarshan P Monga; Steven Strom; Anthony J Demetris; Michael Nalesnik; Yan P Yu; Sarangarajan Ranganathan; George K Michalopoulos
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

3.  Short-term effect of combined therapy with Jinlong Capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression.

Authors:  Guo-lin Wu; Li Zhang; Tian-yi Li; Jiu Chen; Guo-you Yu; Jian-ping Li
Journal:  Chin J Integr Med       Date:  2010-05-16       Impact factor: 1.978

4.  Osteopontin expression in proliferated bile ductules: the correlation with liver damage in fulminant hepatitis.

Authors:  Takuma Tajiri; Genshu Tate; Toshiaki Kunimura; Yutaka Endo; Kazuaki Inoue; Toshiyuki Mitsuya; Toshio Morohoshi; Makoto Yoshiba
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

Review 5.  Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Nai-Kong V Cheung
Journal:  Cancer Lett       Date:  2017-04-17       Impact factor: 8.679

6.  Human mesenchymal stem cell and epithelial hepatic carcinoma cell lines in admixture: concurrent stimulation of cancer-associated fibroblasts and epithelial-to-mesenchymal transition markers.

Authors:  Syamal D Bhattacharya; Zhiyong Mi; Lindsay J Talbot; Hongtao Guo; Paul C Kuo
Journal:  Surgery       Date:  2012-09       Impact factor: 3.982

7.  Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.

Authors:  Renee J Phillips; Karla J Helbig; Kylie H Van der Hoek; Devanshi Seth; Michael R Beard
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

8.  Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea.

Authors:  Taichang Jang; Todd Savarese; Hoi Pang Low; Sunchin Kim; Hannes Vogel; David Lapointe; Timothy Duong; N Scott Litofsky; James M Weimann; Alonzo H Ross; Lawrence Recht
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

9.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

10.  Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH.

Authors:  Jin-Cai Wu; Bing-Sheng Sun; Ning Ren; Qing-Hai Ye; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.